Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orhan Sezer

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Anti-Cancer Drugs|November 5, 2003
Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusionJan Eucker, Daniel Eikel, Ulrike Heider, et al.
European Journal of Haematology|February 8, 2012
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspasesBritta Lamottke, Martin Kaiser, Maren Mieth, et al.
Medizinische Klinik (Munich, Germany : 1983)|October 14, 2006
[Interdisciplinary guidelines for diagnosis and therapy of extracerebral amyloidosis: issued by the German Society of Amyloid Diseases e. V. (www.amyloid.de)]Christoph Röcken, Jutta Ernst, Ernst Hund, et al.
European Journal of Haematology|April 9, 2010
BSc2118 is a novel proteasome inhibitor with activity against multiple myelomaJan Sterz, Christian Jakob, Ulrike Kuckelkorn, et al.
Pharmacogenetics and Genomics|June 15, 2007
Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalanAnnett Kühne, Rolf Kaiser, Markus Schirmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiographyChristian Jakob, Ivana Zavrski, Ulrike Heider, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2007
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomachPernilla Lagergren, Peter Fayers, Thierry Conroy, et al.
Anti-Cancer Drugs|December 23, 2004
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trialPeter Schmid, Jutta Krocker, Carsten-Oliver Schulz, et al.
European Journal of Haematology|December 24, 2009
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myelomaMartin Kaiser, Britta Lamottke, Maren Mieth, et al.
Clinical Lymphoma & Myeloma|December 3, 2009
Serum levels of total-RANKL in multiple myelomaChristian Jakob, Andrea Goerke, Evangelos Terpos, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Anti-Cancer Drugs|November 5, 2003
Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusionJan Eucker, Daniel Eikel, Ulrike Heider, et al.
European Journal of Haematology|February 8, 2012
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspasesBritta Lamottke, Martin Kaiser, Maren Mieth, et al.
Medizinische Klinik (Munich, Germany : 1983)|October 14, 2006
[Interdisciplinary guidelines for diagnosis and therapy of extracerebral amyloidosis: issued by the German Society of Amyloid Diseases e. V. (www.amyloid.de)]Christoph Röcken, Jutta Ernst, Ernst Hund, et al.
European Journal of Haematology|April 9, 2010
BSc2118 is a novel proteasome inhibitor with activity against multiple myelomaJan Sterz, Christian Jakob, Ulrike Kuckelkorn, et al.
Pharmacogenetics and Genomics|June 15, 2007
Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalanAnnett Kühne, Rolf Kaiser, Markus Schirmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiographyChristian Jakob, Ivana Zavrski, Ulrike Heider, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2007
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomachPernilla Lagergren, Peter Fayers, Thierry Conroy, et al.
Anti-Cancer Drugs|December 23, 2004
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trialPeter Schmid, Jutta Krocker, Carsten-Oliver Schulz, et al.
European Journal of Haematology|December 24, 2009
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myelomaMartin Kaiser, Britta Lamottke, Maren Mieth, et al.
Clinical Lymphoma & Myeloma|December 3, 2009
Serum levels of total-RANKL in multiple myelomaChristian Jakob, Andrea Goerke, Evangelos Terpos, et al.
Pageof 11